PHARMACY

Consumer Health World awards Cigna’s online prescription drug price quote tool

BY Drew Buono

BLOOMFIELD, Conn. Cigna’s online prescription drug price quote tool received two awards from Consumer Health World at the organization’s recent conference in Las Vegas. The awards were for Best Innovation Stimulating Consumer Engagement and Best Application for Enhancing Patient Access for Information. The awards recognize excellence and advancement in service, products and programs that enhance consumers’ abilities to manage their health care expenditures and enhance health care quality.

The myCigna.com prescription drug price quote tool enables members in the company’s pharmacy plans to compare the actual price of prescription drugs based on the member’s specific benefit plan. They are able to view the cost of brand name medications, available generics and low cost therapeutically equivalent drug alternatives at their local pharmacies. Other features include Google mapping to easily find a pharmacy and alerts for medications with special requirements. Information about medications and questions for individuals to ask their physicians about their medication or condition is available. The tool also includes discount coupons for clients who have enrolled in Cigna’s Save with Generics program.

“Our goal is to get the people in our health plans to take their medications according to the instructions of their physicians. By taking their medications appropriately, they stay healthier and therefore avoid unnecessary hospitalizations and emergency room visits. The result is lower health care costs,” said Eric Elliott, president of Cigna’s pharmacy management.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Study finds more than half of Americans regularly take prescription meds

BY Alaric DeArment

FRANKLIN LAKES, N.J. For the first time, a majority of Americans with health insurance have some kind of chronic health condition, and young people have experienced the largest increases.

According to research released Wednesday by Medco Health Solutions that examined the prescription claims of around 2.5 million Americans, 51 percent of insured Americans took prescription drugs to treat chronic health problems in 2007. While the elderly still constitute the largest demographic such medications, nearly half of women aged 22 to 44 and a third of men in the same age bracket were also using them. Men and women in that age group experienced a 20 percent increase in use of drugs to treat chronic conditions between 2001 and 2007.

Among men in the 20 to 44 age bracket, drugs to treat hypertension and cholesterol were among the top four, showing an increase in heart disease in this group. Nearly 30 percent of children aged 19 and younger also took chronic medications, mostly to treat asthma, allergies, depression and attention deficit/hyperactivity disorder.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Avastin/Lucentis study may reverberate through industry

BY Drew Buono

NORWALK, Conn. According to IMS Health, a new clinical trial that began this year by a research institute may change the relationship between payers and the pharmaceutical industry, the Financial Times reported.

The National Eye Institute has sponsored a $16 million head-to-head trial of Genentech’s drugs Avastin and Lucentis. Lucentis is approved to treat age-related macular degeneration and Avastin is used to treat cancer but, both drugs are very similar and physicians have been using Avastin off-label for AMD.

The problem with the off-label use is the cost, as a single dose of Lucentis costs $2,000 while a bottle of Avastin can be split up to cost only $40-$75 per injection.

IMS argues that if CATT, the Institute’s study, shows Avastin to be as safe and effective for AMD as Lucentis, it may pave the way for an increasing number of payers to take comparative drug studies out of the hands of the pharmaceutical companies, especially as databases of patients make it much easier to conduct such tests.

But it warns that the move may create a disincentive for companies to study such areas, and creates untested areas of who would approve Avastin for AMD following a late-stage Phase 3 clinical trial which was conducted without any of the usual early-stage testing regulators usually require.

The study is expected to conclude in 2010 and has no involvement with Genentech.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?